Ran Jin, MD, PhD

Amgen Inc.

Poster(s):

• E0400 - Treatment Patterns of an Adalimumab Biosimilar (ABP 501) Among Patients With Inflammatory Bowel Disease: An Observational Study Using German Pharmacy Claims Database
  Tuesday, October 25, 2022

  3:00 PM – 5:00 PM ET